

A Literature Review on the Performance of Tiny Tract for In Vitro Modeling (tiny-TIM) to Predict Food-Drug and pH-Dependent Drug-Drug Interaction Risks

Yuhua Chang^{1,2}, Gang Zhao^{1,2}, Duyen Nguyen², Qi Zhang², Hye Lim Lim²

¹. Oak Ridge Institute for Science and Education, Oak Ridge, TN 37830, USA

². Division of Therapeutic Performance II, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. FDA, Silver Spring, MD 02993, USA



Introduction

- Drug substances can be formulated as amorphous solid dispersions (ASDs) to enhance their solubility and dissolution. However, ASDs are inherently metastable or unstable systems and as such susceptible to crystallization.
- Drug products containing ASDs are classified as high-risk products with regard to bioequivalence because in vivo performance differences due to formulation and/or manufacturing variation may not be detected with a single in vivo bioequivalence study under fasting or fed conditions.
- Tiny-TIM model may provide insights into the bioavailability of various oral dosage forms, considering both fed and fasting conditions.
- The objective of this project was to conduct a literature review of tiny-TIM model and its current predictive performance on the effect of food and elevated pH on the bio-accessibility of active pharmaceutical ingredients (APIs) and ASD products.
- This work may support the utilization of tiny-TIM model for regulatory decisions.

Methods

- Keywords used for literature search: TIM, tiny-TIM, simulation.
- Information collected from literature: APIs, dosage form, formulation, food / pH effect on drug absorption from published clinical data, and food / pH effect predicted by tiny-TIM modelling.

Results

- Tiny-TIM is an intricate and dynamic model designed to replicate the conditions in the stomach and small intestine of the adult human.




Figure 1. Graphical representation of the tiny-TIM model including an advanced gastric compartment (agc). a: meal inlet, b: corpus, c: proximal antrum, d: gastric port, e: distal antrum, f: pyloric valve, g: peristaltic valve, h: small intestinal compartment, i: small intestinal port, j: gastric secretions, k: intestinal secretions, l: pH electrodes, m: filtration system, n: level sensor, o: sample pump, p: sample bottles. Reprinted from Verwei et al., Int J Pharm. 2016 Feb 10;498(1-2):178-86.

A total of 24 drug products were collected from the literature (references available upon request) for TIM modeling prediction (with itraconazole evaluated for both food and pH effect):

- 12 drug products were collected for prediction of food effect (Table 1).
- 13 drug products were collected for prediction of pH effect (Table 2).

The TIM prediction was arbitrarily grouped into three categories to better understand the prediction performance of TIM Modeling:

- High predictability: TIM prediction is deviated < 20% of that of the in vivo data.
- Moderate predictability: TIM prediction is deviated ≥ 20 and < 100% of that of the in vivo data.
- Low predictability: TIM prediction is deviated $\geq 100\%$ of that of the in vivo data.

Table 1. Prediction of food effect using TIM systems (tiny-TIM and TIM-1*) (* indicates data from TIM-1)

APIs	Dosage form	Meal Type	Bio-accessibility Ratio (fed/fasted) from tiny-TIM or TIM-1*	Ratio of AUC (fed/fasted) from clinical studies	Prediction % (TIM/in vivo)*100	Predictability
Danirixin	Tablets	High fat meal	0.6*	0.6	100%	High
Diclofenac	Tablets IR	Ensure Plus	1.0*	1.0	100%	High
Ciprofloxacin	Tablets ER	High fat meal	1.0	1.0	100%	High
Acetaminophen	Tablets IR	Standard meal	1.0*	0.9	111%	High
Acetaminophen	Powder	Infant formula	1.0	1.0	100%	High
Fosamprenavir	Tablets IR	Scandi-shake Mix	1.0*	1.0	100%	High
Ibuprofen	Capsules	High fat meal	1.0	0.9	111%	High
Celecoxib	Capsules	High fat meal	2.0*	1.6	125%	Moderate
Undisclosed drug	Tablets (10 mg)	High fat meal	2.9	2.2	132%	Moderate
Itraconazole	Capsules	High fat meal	3.9	1.6	244%	Low
Nifedipine	Tablets MR	High fat meal	3.6	1.7	218%	Low
Posaconazole	Suspension	High fat meal	12.1	4	303%	Low

Table 2. Prediction of elevated pH effect from acid reducing agents (ARAs) using tiny-TIM system

APIs	Dosage Form	Ratio of bio-accessibility (ARA/Non-ARA) from tiny-TIM	Ratio of AUC (ARA/Non-ARA) from clinical studies	Prediction % (TIM/in vivo)*100	Predictability
GDC-A	Tablets	1	1	100%	High
GDC-E	Tablets	1	1	100%	High
GDC-F	Capsules	1	1	100%	High
Alectinib	Capsules	1	1	100%	High
Dasatinib	Powder	0.4	0.4	100%	High
Dipyridamole	Powder	0.6	0.63	95%	High
Itraconazole	Capsules	0.6	0.55	109%	High
GDC-C	Tablets	0.8	0.75	107%	High
GDC-B	Tablets	0.2	0.33	61%	Moderate
Erlotinib	Powder	0.7	0.5	140%	Moderate
GDC-D	Tablets	0.7	0.46	152%	Moderate
Atazanavir	Capsules	0.7	0.06 - 0.41	171 - 1166%	Low
Ketoconazole	Powder	0.4	0.08	500%	Low

Table 3. A summary of TIM prediction of food effects from Table 1

Food Effect	High Pre	Moderate Pre	Low Pre
Negative	1	0	0
No	6	0	0
Positive	0	2	3

Table 4. A summary of TIM prediction of pH (ARAs) effects from Table 2

pH (ARAs) Effect	High Pre	Moderate Pre	Low Pre
Negative	4	3	2
No	4	0	0

*Pre as in Tables 3 and 4 is abbreviated for Predictability.

Results (continued)

- When food has no effect on drug absorption (n = 6) or had negative effect on drug absorption (n = 1), the TIM prediction deviated < 20% of that of in vivo data. For the five drug products with positive food effect, the TIM prediction deviated from 25% to 203% of that of in vivo data (Tables 1 and 3).
- When elevated pH has no effect on drug absorption (n = 4), the TIM prediction deviated < 20% of that of in vivo data. When elevated pH has negative effect on drug absorption, the TIM modeling prediction has variable performance: deviated < 20% (n = 4), deviated $\geq 20\%$ but < 100% (n = 2), or deviated $\geq 100\%$ (n = 3) from that of in vivo data (Tables 2 and 4).
- Among 24 drug products collected, only one formulated in ASD was evaluated in tiny-TIM modeling (Itraconazole capsule).
 - The food effect is overestimated by 144% compared to clinical studies (Table 1).
 - The pH effect predicted by tiny-TIM is comparable to that from clinical studies (Table 2).

Conclusion

- Tiny-TIM system may reliably predict the effect of food and elevated pH on drug absorption in some cases.
- The tiny-TIM prediction may not always be accurate:
 - It may over-estimate the food effect.
 - It may under-estimate the pH effect.
- This work highlights that additional improvement and validation are needed, in order to apply the tiny-TIM system to investigate the effect of food intake and gastric pH modification on the bio-accessibility of drug products for regulatory decision making including those for generic drugs.

Acknowledgements: Dr. Yuhua Chang is supported in part by an appointment to the Research Participation Program at the U.S. Food and Drug Administration administered by the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the U.S. Department of Energy and the U.S. Food and Drug Administration. Special thanks to Dr. Lei Zhang for her critical review of this poster.

Disclaimer: The poster reflects the views of the authors and should not be construed to represent FDA's views or policies.

